Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) and Belgian biopharma firm TiGenix (Euronext Brussels: TIG) have entered into a licensing, development and commercialization agreement for Crohn’s disease treatment Cx601 outside the USA.
TiGenix will receive an upfront cash payment of 25 million euros ($27.86 million) and will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of 355 million euros and double-digit royalties on net sales by Takeda.
The first anticipated milestone payment is 15 million euros upon obtaining the Marketing Authorization of Cx601 in Europe. Takeda will also make an equity investment of €10 million in the share capital of TiGenix within the next 12 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze